These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8222159)

  • 1. Neoplastic disorders after pediatric heart transplantation.
    Bernstein D; Baum D; Berry G; Dahl G; Weiss L; Starnes VA; Gamberg P; Stinson EB
    Circulation; 1993 Nov; 88(5 Pt 2):II230-7. PubMed ID: 8222159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression.
    Armitage JM; Kormos RL; Stuart RS; Fricker FJ; Griffith BP; Nalesnik M; Hardesty RL; Dummer JS
    J Heart Lung Transplant; 1991; 10(6):877-86; discussion 886-7. PubMed ID: 1661607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreasing incidence of coronary disease in pediatric cardiac transplant recipients using increased immunosuppression.
    Addonizio LJ; Hsu DT; Douglas JF; Kichuk MR; Michler RE; Quaegebeur JM; Smith CR; Rose EA
    Circulation; 1993 Nov; 88(5 Pt 2):II224-9. PubMed ID: 8222158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of immunosuppression in cyclosporine-treated heart transplant patients with lymphoma.
    Brumbaugh J; Baldwin JC; Stinson EB; Oyer PE; Jamieson SW; Bieber CP; Henle W; Shumway NE
    J Heart Transplant; 1985 May; 4(3):307-11. PubMed ID: 3039097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F; Kunitake H; Laks H; Odim J
    Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection after pediatric heart transplantation: results of a multiinstitutional study. The Pediatric Heart Transplant Study Group.
    Schowengerdt KO; Naftel DC; Seib PM; Pearce FB; Addonizio LJ; Kirklin JK; Morrow WR
    J Heart Lung Transplant; 1997 Dec; 16(12):1207-16. PubMed ID: 9436132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-drug immunosuppression for heart transplantation in infants and children.
    Brown JW; Turrentine MW; Kesler KA; Mahomed Y; Darragh R; Evans K; Thompson L; Caldwell R
    J Heart Lung Transplant; 1993; 12(6 Pt 2):S265-74. PubMed ID: 8312346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
    Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
    Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation.
    Cox KL; Lawrence-Miyasaki LS; Garcia-Kennedy R; Lennette ET; Martinez OM; Krams SM; Berquist WE; So SK; Esquivel CO
    Transplantation; 1995 Feb; 59(4):524-9. PubMed ID: 7533344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.
    Kirklin JK; Naftel DC; Levine TB; Bourge RC; Pelletier GB; O'Donnell J; Miller LW; Pritzker MR
    J Heart Lung Transplant; 1994; 13(3):394-404. PubMed ID: 8061014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
    J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.